Journal of Clinical ImmunologyCrespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, Sobel RA, Steinman L, Robinson WH. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol. 2011. doi:10.1007/s10875-011-9579-6....
tumor growth. These previous findings shed light on combining C5a/C5aR blockade and PD-1/PD-L1 inhibitors to synergistically inhibit the tumor growth. Recently, Corrales and colleagues reported that combined inhibition of PD-1 and C5a impairs lung cancer growth and metastasis with reducing the ...
别名 Phosphotyrosine kinase 简介- 关联 5,047 项与Tyrosine kinase 相关的药物 Tasurgratinib 靶点 FGFR1 x FGFR2 x FGFR3 作用机制 FGFR1拮抗剂 [+2] 在研机构 Eisai Co., Ltd. 原研机构 Eisai Co., Ltd. 在研适应症 FGFR2融合或重排的胆管癌 [+4] 非在研适应症- 最高研发阶段批准上市 首次获批...
In B cells, the key member of this kinase family is Bruton tyrosine kinase (BTK), which is mutated in X-linked agammaglobulinemia. Ibrutinib is a BTK inhibitor that has shown promise in the treatment of B-cell malignancies19; such inhibitors may also be useful in the treatment of ...
Tyrosine kinase-IN-7 is a potent inhibitor of the tyrosine kinase EGFR, inhibiting EGFR(WT) and EGFR(T790M) and showing anti-cancer and anti-tumor activity in a variety of cancer cell lines. Tyrosine kinase-IN-7 has potential anti-inflammatory and antiviral activities. ...
PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression Jai Nien Tung, Po Lin Lin, Yao Chen Wang, De Wei Wu, Chi Yi Chen, Huei Lee 癌症生物學與藥物研發博士學位學程...
Opposing effects of protein tyrosine kinase inhibitors on the monoclonal antibody induced internalization of CD3 and CD4 antigens 喜欢 0 阅读量: 20 作者:L Thuillier,J Pérignon,Franoise Selz,C Griscelli,A Fischer 摘要: We have previously demonstrated that the monoclonal antibody (mAb)-induced ...
PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases Can Zhu Zimo Yang Wanli Liu Cell Discovery (2024) Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents Nee...
Taken together, these findings strongly suggest that Blk is a potential therapeutic target in CTCL for dasatinib and other clinical-grade dual- specificity Bcr-Abl and Src family kinase inhibitors. As dasatinib and other dual-specific inhibitors are already used in treatment of other hematological ...
Bruton's tyrosine kinase is acytoplasmic proteini.e. critical for downstream B-cell receptor signaling. The pharmacologic inhibition of BTK results in anti-tumor activity in several B-cellmalignancies, includingMCL. At present, 3 irreversibleBTK inhibitors–ibrutinib,acalabrutinib, andzanubrutinib– ...